Bath scientists stabilise vaccine proteins with ensilication
A new system for delivering vaccines to children in low-income nations has taken a vital step forward, thanks to groundbreaking work at the University of Bath
Vaccines are notoriously difficult to transport to remote or dangerous places, as they spoil when not refrigerated. Formulations are safe between 2°C and 8°C, but at other temperatures the proteins start to unravel, making the vaccines ineffective. As a result, millions of children around the world miss out on life-saving inoculations.
However, scientists have now found a way to prevent warmed-up vaccines from degrading. By encasing protein molecules in a silica shell, the structure remains intact even when heated to 100°C, or stored at room temperature for up to three years.
The technique for tailor-fitting a vaccine with a silica coat – known as ensilication – was developed by a Bath team in collaboration with the University of Newcastle. This pioneering technology was seen to work in the lab two years ago, and now it has demonstrated its effectiveness in the real world too.
The researchers explain the significance of their findings
In their latest study, published in the journal Scientific Reports, the researchers sent both ensilicated and regular samples of the tetanus vaccine from Bath to Newcastle by ordinary post (a journey time of over 300 miles, which by post takes a day or two). When doses of the ensilicated vaccine were subsequently injected into mice, an immune response was triggered, showing the vaccine to be active. No immune response was detected in mice injected with unprotected doses of the vaccine, indicating the medicine had been damaged in transit.
Dr Asel Sartbaeva, who led the project from the University of Bath’s Department of Chemistry, said: “This is really exciting data because it shows us that ensilication preserves not just the structure of the vaccine proteins but also the function – the immunogenicity.”
“This project has focused on tetanus, which is part of the DTP (diphtheria, tetanus and pertussis) vaccine given to young children in three doses. Next, we will be working on developing a thermally-stable vaccine for diphtheria, and then pertussis. Eventually we want to create a silica cage for the whole DTP trivalent vaccine, so that every child in the world can be given DTP without having to rely on cold chain distribution.”
Cold chain distribution requires a vaccine to be refrigerated from the moment of manufacturing to the endpoint destination.
Silica is an inorganic, non-toxic material, and Dr Sartbaeva estimates that ensilicated vaccines could be used for humans within five to 15 years. She hopes the technology to silica-wrap proteins will eventually be adopted to store and transport all childhood vaccines, as well as other protein-based products, such as antibodies and enzymes.
“Ultimately, we want to make important medicines stable so they can be more widely available,” she said. “The aim is to eradicate vaccine-preventable diseases in low income countries by using thermally stable vaccines and cutting out dependence on cold chain.”
Currently, up to 50% of vaccine doses are discarded before use due to exposure to suboptimal temperatures. According to the World Health Organisation (WHO), 19.4 million infants did not receive routine life-saving vaccinations in 2018.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Bolsonaro says China fast-tracking supplies for COVID-19 vaccines made in Brazilon January 25, 2021 at 11:56 am
Brazil's President Jair Bolsonaro thanked China on Monday for rapidly approving export of 5,400 liters of inputs for Sinovac's vaccine being made in Sao Paulo as his government scrambles to secure ...
- Brazil buying as many vaccines as it can, criticism unwarranted, says economy ministeron January 25, 2021 at 11:34 am
Brazil is trying to buy as many COVID-19 vaccines as possible, and accusations it has focused its efforts on only one manufacturer are unjust, Economy Minister Paulo Guedes said on Monday. Speaking ...
- Mayor Lori Lightfoot unveils plan to send more COVID-19 vaccines to Black and Latino neighborhoodson January 25, 2021 at 11:23 am
In an effort to boost COVID-19 vaccination rates in hard-hit Black and Latino neighborhoods, Mayor Lori Lightfoot said Monday she plans to increase the number of doses for mostly South and West Side ...
- Merck drops two potential COVID-19 vaccines after poor results in early testingon January 25, 2021 at 10:00 am
Merck is pulling the plugs on two potential COVID-19 vaccines following poor results in early-stage studies. The drugmaker said Monday it will focus instead on studying two possible treatments for the ...
- Will cruises require vaccines? One line just set a standard.on January 25, 2021 at 9:21 am
Saga Cruises, based in the UK, will require passengers to get both doses and wait at least 14 days before departing.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Electric car battery that can recharge in 10 minutes and last for 250 miles on a single charge could help drivers combat 'range anxiety'on January 18, 2021 at 8:01 am
The cathode is thermally stable lithium iron phosphate, which does not contain any of the expensive and critical materials like cobalt. While the anode is made of very large particle graphite ...
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™on January 12, 2021 at 10:55 pm
Bio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 . iosBio licenses its Or ...
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro(TM) oral vaccine platform technology for COVID-19on January 12, 2021 at 1:51 pm
OraPro(TM) is iosBio's patented oral delivery vaccine platform technology that enables oral administration of thermally-stable, viral vector vaccines. These vaccine vectors are engineered to ...
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19on January 12, 2021 at 6:36 am
OraPro™ is iosBio’s patented oral delivery vaccine platform technology that enables oral administration of thermally-stable, viral vector vaccines. These vaccine vectors are engineered to withstand ...
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 | Morningstaron January 12, 2021 at 4:30 am
Tax Planning Personal Finance Save for College Save for Retirement Invest in Retirement Research Mutual Funds Stocks ETFs Bonds Best Investments ...